Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Intercept Pharmaceuticals (ICPT)

Intercept Pharmaceuticals (ICPT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Intercept Pharmaceuticals 305 Madison Avenue Morristown NJ 07960 USA

www.interceptpharma.com P: 646-747-1000

Description:

Intercept Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing novel therapeutics to treat chronic liver diseases to market. The company's focus is on treating orphan and more prevalent liver diseases with limited treatment options. The company received FDA approval for Ocaliva an farnesoid X receptor against in combination with ursodeoxycholic acid, for the treatment of primary biliary cholangitis in adults with an inadequate response to UDCA or as monotherapy in adults who are intolerant to UDCA. Ocaliva was approved in the EU for the same indication. The drug was approved in Canada. OCA is also being developed for additional indications like primary sclerosing cholangitis and non-alcoholic steatohepatitis. The FDA accepted its New Drug Application for OCA seeking accelerated approval for the treatment of fibrosis due to NASH. Intercept received a complete response letter from the FDA stating that its NDA for OCA for the treatment of liver fibrosis due to NASH could not be approved.

Key Statistics

Overview:

Market Capitalization, $K 793,877
Enterprise Value, $K 1,070,687
Shares Outstanding, K 41,783
Annual Sales, $ 285,710 K
Annual Net Income, $ 221,820 K
Last Quarter Sales, $ 83,720 K
Last Quarter Net Income, $ -5,860 K
EBIT, $ -83,330 K
EBITDA, $ -80,760 K
60-Month Beta 0.88
% of Insider Shareholders 6.20%
% of Institutional Shareholders 83.81%
Float, K 39,192
% Float 93.80%
Short Volume Ratio 0.43

Growth:

1-Year Return 24.02%
3-Year Return -49.83%
5-Year Return -81.50%
5-Year Revenue Growth 118.17%
5-Year Earnings Growth 82.89%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.07 on 11/06/23
Latest Earnings Date 11/07/23
Earnings Per Share ttm -4.37
EPS Growth vs. Prev Qtr 50.00%
EPS Growth vs. Prev Year 97.70%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

ICPT Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -189.98%
Return-on-Assets % -30.32%
Profit Margin % 77.64%
Debt/Equity 3.31
Price/Sales 2.77
Price/Cash Flow N/A
Price/Book 11.05
Book Value/Share 1.62
Interest Coverage -7.17
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar